I-Mab Stock Price, News & Analysis

I-Mab (NASDAQ: IMAB) reported its full year 2024 financial results, highlighting progress in its givastomig Phase 1b combination trial for first-line gastric cancer. The company completed enrollment ahead of schedule in the first expansion cohort, with topline dose escalation data expected in 2H 2025.

Financial highlights include a strong cash position of $173.4 million as of December 31, 2024, providing runway into 2027. The company reported a net loss of $22.2 million for 2024, compared to $207.7 million in 2023. R&D expenses were $21.8 million, while administrative expenses reached $29.7 million.

Key developments include the completion of Greater China assets divestiture and business operations restructuring. The company is focusing on advancing givastomig, a CLDN18.2 x 4-1BB bispecific antibody, with Phase 1b dose expansion study results expected in 1H 2026.

I-Mab (NASDAQ: IMAB), a US-based global biotech company specializing in precision immuno-oncology treatments for cancer, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled to take place from April 7-10, 2025.

The company's management team will be present at this virtual healthcare event, which serves as a significant platform for biotechnology companies to showcase their developments and connect with industry stakeholders.

I-Mab (NASDAQ: IMAB) has received a deficiency notice from Nasdaq on March 19, 2025, for failing to meet the minimum bid price requirement of $1.00. The notice comes after the company's stock traded below this threshold from February 3 to March 18, 2025.

The company has been granted a 180-day compliance period until September 15, 2025, during which it must achieve a closing bid price of at least $1.00 for ten consecutive business days to maintain its Nasdaq Global Market listing. If unsuccessful, I-Mab may be eligible for an additional 180-day extension or face potential delisting.

While the notice does not immediately affect I-Mab's listing status, business operations, or SEC reporting requirements, the company is evaluating options to regain compliance and has expressed its intention to resolve the deficiency within the given timeframe.

I-Mab (NASDAQ: IMAB) has announced accelerated progress in its Phase 1b givastomig study, with completed enrollment in the first dose expansion cohort ahead of schedule and continued momentum in the second cohort. The study evaluates givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, for first-line gastric cancer treatment.

The Phase 1b program consists of a dose escalation study (n=17) and a dose expansion study (n=40). Topline data from the dose escalation study is expected in 2H 2025, while results from the 40-patient dose expansion study are anticipated in 1H 2026.

The study aims to assess givastomig's safety, preliminary efficacy, and pharmacokinetics in combination with standard care (nivolumab plus chemotherapy). Early data shows encouraging results, with the drug demonstrating activity across various CLDN18.2 expression levels and favorable tolerability when combined with chemotherapy and anti-PD-1 checkpoint inhibitors.

I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on precision immune-oncology agents for cancer treatment, has announced its participation in the Leerink Partners Global Healthcare Conference. The conference will take place in Miami, Florida on March 11-12, 2025, where I-Mab's management team will engage in one-on-one meetings with conference attendees.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.

The company's management team will deliver a presentation on Tuesday, February 11, 2025, from 4:00 to 4:30 PM ET. The presentation will be accessible via webcast, and the company will also participate in one-on-one meetings during the conference.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology, announced that Wei Fu, the Chairman of the Board, plans to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) in open market transactions. These purchases will be executed via his controlled entity, although the exact number of ADSs and the timeframe for acquisition remain uncertain.

Wei Fu stated that the Board and senior leadership successfully executed the corporate strategy for 2024, aligning with the long-term goal of increasing shareholder value. The company recently prioritized its portfolio, designating givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, as its lead clinical program. Data from a dose escalation study combining givastomig with nivolumab and chemotherapy are expected in early H2 2025, with a 40-patient dose expansion study data anticipated in early 2026.

The company's current cash runway extends into 2027.

I-Mab (NASDAQ: IMAB) has announced a strategic portfolio prioritization focusing on givastomig, its lead clinical program targeting first-line metastatic gastric cancers. The company has completed enrollment for a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, with data expected in early H2 2025.

A 40-patient dose expansion study is ongoing with results anticipated in early 2026. The company's cash balance of $184.4 million (as of September 30, 2024) is expected to support operations into 2027.

Phase 1 trials showed an overall response rate of 16.3% (7/43) for givastomig monotherapy, with favorable safety profiles. The company is pausing the development of uliledlimab to focus resources on givastomig, while maintaining its partnership with ABL Bio for ragistomig development.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York from December 3-5, 2024. The company's management team will deliver a presentation on December 4 at 4:30 p.m. ET. Key participants include CEO Sean Fu, CMO Phillip Dennis, CFO Joseph Skelton, and Senior Director of IR Tyler Ehler. The event will feature one-on-one and small group meetings during December 3-4. A webcast of the presentation will be accessible through the company's IR website.